SMO and skin basal cell carcinoma: One good example is that abnormal activation of Smoothened (Smo), an atypical G protein-coupled receptor (GPCR), results in basal cell carcinoma (BCC) and medulloblastoma1, 2, therefore Smo has been an attractive therapeutic target, exemplified by the newly FDA approved drugs6.